Lixte Biotechnology (LIXT)
Develops LB-100 and proton therapy technology for cancer treatment.
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
-- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment and Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla. , July 06, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company"), today announced that it has completed its name change from LIXTE Biotechnology Holdings, Inc.
LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name Change to NOMAD Power Solutions BOCA RATON, Fla. /WATERBURY, Vt. , July 02, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) ("LIXTE" or the "Company") today announced it has completed the previously announced merger with NOMAD Transportable Power Systems, Inc.
LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name Change to NOMAD Power Solutions
LIXTE Joins Russell Microcap Index
BOCA RATON, Fla. , June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap Index, effective after the close of the U. S. equity markets on June 26, 2026, as part of the annual Russell U.
LIXTE Joins Russell Microcap Index
BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap® Index, effective after the close of the U.S. equity markets on June 26, 2026, as part of the annual Russell U.S. Indexes reconstitution. The reconstituted indexes will take effect at the opening of trading on Monday, June 29, 2026.
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol BOCA RATON, Fla. & WATERBURY, Vt.
The New Bottleneck Isn’t Computing Power — It’s Just Power
Issued on behalf of LIXTE Biotechnology Holdings, Inc. America can build data centers in months, but the electricity to run them can take half a decade to arrive. That gap is becoming one of the biggest investment stories of the decade - and a NASDAQ-listed company is repositioning itself to sit right inside it.
LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar Power Capacity Opportunity BOCA RATON, Fla. and WATERBURY, Vt. , June 12, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) ("LIXTE" or the "Company") today announced that it has entered into a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, Inc.
LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar Power Capacity Opportunity
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure BOCA RATON, Fla. , June 01, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), today announced its strategic transformation into an AI energy infrastructure equipment and services platform focused on meeting the rapidly growing power demands of AI and hyperscale data centers.
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (“SEC”) for the first quarter ended March 31, 2026. The report is available on the Company's website, www.lixte.com, and on the SEC's website, www.sec.gov.
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
-Trial Combines LIXTE's LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options-
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company's website, www.lixte.com, and on the SEC's website, www.sec.gov.
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary (“Liora”).
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the inaugural Good Health: Mind, Body & Soul Summit will take place February 19 at Morehouse College in Atlanta. This invitation-only event brings together leaders in health, culture, science, and community to advance health equity for Black men and families.
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced the Company will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey, January 28-29, 2026. Geordan Pursglove, LIXTE's Chief Executive Officer, will conduct one-on-one meetings with investors during the conference.
Lixte Biotechnology (NASDAQ:LIXT) Trading Up 0.5% – Here’s Why
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT - Get Free Report)'s share price traded up 0.5% during trading on Friday. The stock traded as high as $4.14 and last traded at $4.07. 38,006 shares changed hands during mid-day trading, a decline of 53% from the average session volume of 81,454 shares. The stock had previously closed
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a biotech company focused on advancing cancer treatments, today announced it is expanding its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial with LIXTE's proprietary compound, LB-100, to treat ovarian clear cell cancer.
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
New York, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, announces its role as exclusive placement agent in a $4. 3 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT). Lixte Biotechnology Holdings, Inc.